Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Sponsor: Ludwig Institute for Cancer Research
A PHASE2 clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is completed. The trial is conducted by Ludwig Institute for Cancer Research and has accumulated 9 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Nov 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ludwig Institute for Cancer Research
- Roswell Park Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .